Cargando…

Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa

INTRODUCTION: Andexanet alfa (andexanet) is an approved antidote used to reverse the bleeding effects of Direct Oral Anticoagulant (Direct-Xa agents) agents because it reverses anti-Xa activity. Unfractionated heparin (UFH) and low molecular weight heparins (LMWHs) exhibit anti-Xa activity. The purp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lewis, Joseph, Iqbal, Omer, Jeske, Walter, Hoppensteadt, Debra, Siddiqui, Fakiha, Fareed, Jawed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Manuscript
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096191/ https://www.ncbi.nlm.nih.gov/pubmed/35535398 http://dx.doi.org/10.1177/10760296221099934

Ejemplares similares

Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa
por: Siddiqui, Fakiha, et al.
Publicado: (2020)

Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban by Andexanet Alfa as Measured by Whole Blood Thromboelastographic Analysis
por: Mehrotra, Siddharth, et al.
Publicado: (2022)

Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values
por: Siddiqui, Fakiha, et al.
Publicado: (2019)

Potency Adjusted Blended Heparin of Bovine, Ovine, and Porcine Heparin Exhibit Comparable Biologic Effects to Referenced Single-Sourced Porcine Heparin
por: Olson, Guy, et al.
Publicado: (2023)

Thrombin Generation Profile in Various Lymphoma Sub-Groups and Its Augmentation by Andexanet Alfa
por: Siddiqui, Fakiha, et al.
Publicado: (2020)

Comparative Studies on the Anticoagulant Profile of Branded Enoxaparin and a New Biosimilar Version
por: Qneibi, Dalia, et al.
Publicado: (2020)

Predictive Role of Blood Cellular Indices and Their Relationship with Endogenous Glycosaminoglycans as Determinants of Inflammatory Biomarkers in Pulmonary Embolism
por: Kantarcioglu, Bulent, et al.
Publicado: (2022)

Comparative Anticoagulant and Thrombin Generation Inhibitory Profile of Heparin, Sulodexide and Its Components
por: Siddiqui, Fakiha, et al.
Publicado: (2020)

Bovine Mucosal Heparins Are Comparable to Porcine Mucosal Heparin at USP Potency Adjusted Levels
por: Jeske, Walter, et al.
Publicado: (2019)

Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum
por: Siddiqui, Fakiha, et al.
Publicado: (2019)

Update on the safety and bioequivalence of biosimilars – focus on enoxaparin
por: Jeske, Walter, et al.
Publicado: (2013)

The Relevance of Anti-PF4 Antibody Isotypes and Endogenous Glycosaminoglycans and their Relationship with Inflammatory Biomarkers in Pulmonary Embolism Patients
por: Kantarcioglu, Bulent, et al.
Publicado: (2022)

The Relevance of Thrombo-Inflammatory Biomarkers and Their Relationship with Circulating Glycosaminoglycans in End-Stage Renal Disease Patients
por: Allen, Madeline, et al.
Publicado: (2023)

Comparative Pharmacokinetic Profile of 3 Batches of Ovine Low-Molecular-Weight Heparin and 1 Batch of Branded Enoxaparin
por: Jeske, Walter, et al.
Publicado: (2018)

Comparative Pharmacological Profiles of Various Bovine, Ovine, and Porcine Heparins
por: Kouta, Ahmed, et al.
Publicado: (2019)

Comparison of Low-Molecular-Weight Heparins Prepared From Ovine Heparins With Enoxaparin
por: Chen, Jianle, et al.
Publicado: (2019)

Glycemic Control and Plasma Levels of Pro-Inflammatory and Pro-Thrombotic Biomarkers in Diabetic Patients Presenting with Acute Pulmonary Embolism
por: O’Hara, Alexander, et al.
Publicado: (2023)

Collagen Remodeling and Fatty Acid Regulation Biomarkers in Understanding the Molecular Pathogenesis of Atrial Fibrillation
por: Odeh, Ameer, et al.
Publicado: (2022)

Interrelationship Between Inflammatory Biomarkers and Collagen Remodeling Proteins in Atrial Fibrillation
por: Odeh, Ameer, et al.
Publicado: (2023)

Andexanet-Alfa-Associated Heparin Resistance in the Context of Hemorrhagic Stroke
por: Müther, Michael, et al.
Publicado: (2022)

Difficult Intraoperative Heparinization Following Andexanet Alfa Administration
por: Watson, C. James, et al.
Publicado: (2019)

Successful use of an antithrombin for heparin resistance with andexanet alfa
por: Honda, Jun, et al.
Publicado: (2023)

Fibrinolytic Status and Risk of Death After Acute Pulmonary Embolism
por: Brailovsky, Yevgeniy, et al.
Publicado: (2023)

Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients
por: McGarry, Lisa J, et al.
Publicado: (2006)

Public Perceptions of Current COVID-19 Vaccinations. Results of a Pilot Survey
por: Kantarcioglu, Bulent, et al.
Publicado: (2021)

Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding
por: Stevens, Victoria M., et al.
Publicado: (2021)

Successful Nafamostat Mesilate Administration for Andexanet Alfa-Induced Heparin Resistance
por: Kitaura, Atsuhiro, et al.
Publicado: (2023)

Effectiveness, safety, and costs of thromboprophylaxis with enoxaparin or unfractionated heparin in inpatients with obesity
por: Amin, Alpesh, et al.
Publicado: (2023)

Costs and Healthcare Resource Utilization Associated with Idarucizumab or Andexanet Alfa Oral Anticoagulant Reversal in Patients Hospitalized with Life-Threatening Bleeds
por: Spyropoulos, Alex C., et al.
Publicado: (2022)

Andexanet Alfa Versus Prothrombin Complex Concentrates/Blood Products as Apixaban/Rivaroxaban Reversal Agents: A Survey Among Pediatric Hematologists
por: Rodriguez, Vilmarie, et al.
Publicado: (2022)

Cost-utility of enoxaparin compared with unfractionated heparin in unstable coronary artery disease
por: Nicholson, Tricia, et al.
Publicado: (2001)

Pharmacological Differentiation of Thrombomodulin Alfa and Activated Protein C on Coagulation and Fibrinolysis In Vitro
por: Tanaka, Kosuke, et al.
Publicado: (2018)

Andexanet Alfa: First Global Approval
por: Heo, Young-A
Publicado: (2018)

Institutional Experience of Using Andexanet Alfa
por: Khadka, Sushmita, et al.
Publicado: (2020)

Studies on Tissue Factor Pathway Inhibitor Antigen Release by Bovine, Ovine and Porcine Heparins Following Intravenous Administration to Non-Human Primates
por: Kouta, Ahmed, et al.
Publicado: (2020)

In-hospital Mortality Rates in SARS-CoV-2 Patients Treated with Enoxaparin and Heparin
por: Alroomi, Moudhi, et al.
Publicado: (2022)

The Relationship Between Thrombo-Inflammatory Biomarkers and Cellular Indices of Inflammation in Lymphoma Patients
por: Jaradeh, Mark, et al.
Publicado: (2021)

Arterial-renal Syndrome in Patients with ESRD, a New Disease Paradigm
por: Goldstein, Jake, et al.
Publicado: (2022)

Enoxaparin is associated with lower rates of mortality than unfractionated Heparin in hospitalized COVID-19 patients
por: Pawlowski, Colin, et al.
Publicado: (2021)

Enoxaparin may be associated with lower rates of mortality than unfractionated heparin in neurocritical and surgical patients
por: Samuel, Sophie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rb54qsgkgg5vb9jvb73bv8uiq5